Zoltán Grosz

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf et al. · The Lancet Neurology · 2021 · 169 citations · Full text

Late-onset Pompe Disease, Autoimmune Disease, Clinical Infectious Disease +3

Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients

Léna Szabó, Anita Gergely, Rita Jakus et al. · European Journal of Paediatric Neurology · 2020 · 55 citations · Full text

Genetic background of the hereditary spastic paraplegia phenotypes in Hungary — An analysis of 58 probands

Péter Balicza, Zoltán Grosz, Michael Gonzalez et al. · Journal of the Neurological Sciences · 2016 · 38 citations

Genetic Disorder, Medicine, Genetics +7

Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial

Wolfgang Köhler, Marc Engelen, Florian Eichler et al. · The Lancet Neurology · 2023 · 38 citations · Full text

Non-pharmacological Intervention, Disease Progression, Diabetic Neuropathy +6

Genotypic and phenotypic spectrum of the most common causative genes of Charcot-Marie-Tooth disease in Hungarian patients

György Máté Milley, Edina Varga, Zoltán Grosz et al. · Neuromuscular Disorders · 2017 · 29 citations

Hungarian Patients, Mendelian Disorder, Charcot-marie-tooth Disease +7